Baldness is difficult to cure because current treatments like finasteride, dutasteride, and minoxidil only prevent hair shedding, and new developments are mostly ineffective. Botox shows potential in aiding skin regeneration and hair growth, but maintenance therapy with treatments like dutasteride and minoxidil may still be necessary.
Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.
A 16 year old's experience with using pyrilutamide to treat hair loss, and the potential side effects of adding tretinoin to minoxidil and finasteride treatments.
CRISPR Cas9 could potentially treat baldness by targeting specific genes in hair follicles without affecting other body functions. There is optimism about its future use, despite ethical concerns and the current reliance on treatments like minoxidil and finasteride.
User is using minoxidil with tretinoin 0.025% and experiencing peeling and burning on the scalp. They are unsure if it's effective or if they are using it too frequently.
A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
miR-205, a tiny RNA, can stimulate hair growth by softening aging hair follicle stem cells in mice. Future tests aim to see if this can work in humans.
PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.
Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.
The VT Reedle Shot, a skincare product using silica spicules, is discussed as a potential at-home alternative to microneedling for hair regrowth. It is suggested that different intensities may aid in hairline regrowth.
Retinol or tretinoin may improve minoxidil absorption and effectiveness. The user is considering using The Ordinary's 1% retinol as tretinoin is hard to get in their country.
PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.
People are discussing how to apply tretinoin to the scalp for hair loss treatment and managing scalp dryness. Specific treatments mentioned include tretinoin, minoxidil (Min), finasteride (Fin), and RU58841 (RU).
A drug that regrows body parts, but not hair, sparking debate on hair loss treatments. Discussions include the use of finasteride, dutasteride, and the potential for new methods to restore hair.
The conversation discusses hair regrowth using dissolvable microneedles loaded with rapamycin and epigallocatechin gallate nanoparticles. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.
Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.
The conversation discusses a hair loss treatment regimen involving a homemade topical solution of Minoxidil and Tretinoin, combined with Finasteride and microneedling. Users share advice on Tretinoin application, emphasizing gradual use to avoid skin irritation.
The user has been using minoxidil for 5 years and finasteride for 7 months, with recent addition of tretinoin cream causing significant hair shedding. Other users suggest the shedding indicates effectiveness and recommend continuing tretinoin use.
The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.
The conversation discusses hair regrowth using 0.1% finasteride, 5% minoxidil, 1% retinoid, weekly microneedling, and red light therapy, with noticeable improvement in a short time. One person is curious about the retinoid application process when used with minoxidil.
PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.
Verteporfin reduces scar tissue in hair transplants but doesn't significantly regrow hair follicles. More testing is needed to determine its effectiveness.
The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.